OSIS · Insider Trading
OSI Systems Inc
Every open-market purchase and sale reported by OSIS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-26 | Michael Tropeano | PRESIDENT, RAPISCAN SYSTEMS | MIXED | +188 | +$38.87K |
| 2026-08-26 | Cary M. Okawa | CHIEF ACCOUNTING OFFICER | MIXED | +448 | +$92.62K |
| 2026-08-26 | Victor S Sze | GENERAL COUNSEL | MIXED | +1,846 | +$381.62K |
| 2026-08-26 | Paul Keith Morben | PRES., OPTOELECTRONICS DIV | MIXED | −248 | −$51.27K |
| 2026-08-25 | Deepak Chopra | Director | MIXED | −3,137 | −$648.51K |
| 2026-08-25 | Glenn Grindstaff | CHIEF HUMAN RESOURCES OFFICER | MIXED | +261 | +$53.96K |
| 2026-08-25 | Cary M. Okawa | CHIEF ACCOUNTING OFFICER | F | −118 | −$24.39K |
| 2026-08-25 | Ajay Mehra | PRESIDENT AND CEO | MIXED | +87 | +$17.99K |
| 2026-08-25 | Alan I Edrick | EVP & CFO | MIXED | +2,494 | +$515.58K |
| 2026-08-21 | Kelli Bernard | Director | F | −78 | −$17.23K |
| 2026-08-21 | Deepak Chopra | Director | F | −153 | −$33.80K |
| 2026-08-21 | Gerald M Chizever | Director | F | −88 | −$19.44K |
| 2026-08-21 | James B Hawkins | Director | F | −90 | −$19.88K |
| 2026-08-17 | Kelli Bernard | Director | F | −126 | −$28.80K |
| 2026-08-17 | Gerald M Chizever | Director | F | −141 | −$32.23K |
| 2026-08-17 | James B Hawkins | Director | F | −144 | −$32.91K |
| 2026-08-04 | Paul Keith Morben | PRES., OPTOELECTRONICS DIV | A | +1,491 | +$330.09K |
| 2026-08-04 | Glenn Grindstaff | CHIEF HUMAN RESOURCES OFFICER | A | +610 | +$135.05K |
| 2026-08-04 | Michael Tropeano | PRESIDENT, RAPISCAN SYSTEMS | A | +1,694 | +$375.03K |
| 2026-08-04 | Ajay Mehra | PRESIDENT AND CEO | A | +13,551 | +$3.00M |
| 2026-08-04 | W Paul Constantine | PRES., SPACELABS HEALTHCARE | A | +610 | +$135.05K |
| 2026-08-04 | Alan I Edrick | EVP & CFO | A | +8,514 | +$1.88M |
| 2026-08-04 | Cary M. Okawa | CHIEF ACCOUNTING OFFICER | A | +632 | +$139.92K |
| 2026-08-04 | Victor S Sze | GENERAL COUNSEL | A | +6,437 | +$1.43M |
| 2026-07-29 | James B Hawkins | Director | F | −170 | −$36.94K |
| 2026-07-29 | Kelli Bernard | Director | F | −149 | −$32.38K |
| 2026-07-29 | Gerald M Chizever | Director | F | −166 | −$36.07K |
| 2026-07-21 | James B Hawkins | Director | A | +924 | +$200.18K |
| 2026-07-21 | Deepak Chopra | Director | A | +924 | +$200.18K |
| 2026-07-21 | William Francis Ballhaus JR | Director | A | +924 | +$200.18K |
| 2026-07-21 | Gerald M Chizever | Director | A | +924 | +$200.18K |
| 2026-07-21 | Kelli Bernard | Director | A | +924 | +$200.18K |
| 2026-07-07 | James B Hawkins | Director | F | −231 | −$51.23K |
| 2026-07-07 | Kelli Bernard | Director | F | −202 | −$44.80K |
| 2026-07-07 | Gerald M Chizever | Director | F | −231 | −$51.23K |
| 2026-07-01 | Alan I Edrick | EVP & CFO | A | +75 | +$10.55K |
| 2026-07-01 | Cary M. Okawa | CHIEF ACCOUNTING OFFICER | A | +28 | +$5.21K |
| 2026-07-01 | W Paul Constantine | PRES., SPACELABS HEALTHCARE | A | +55 | +$10.22K |
| 2026-07-01 | Paul Keith Morben | PRES., OPTOELECTRONICS DIV | A | +75 | +$10.55K |
| 2026-07-01 | Michael Tropeano | PRESIDENT, RAPISCAN SYSTEMS | A | +75 | +$10.55K |
| 2026-07-01 | Glenn Grindstaff | CHIEF HUMAN RESOURCES OFFICER | A | +17 | +$3.16K |
| 2026-07-01 | Victor S Sze | GENERAL COUNSEL | A | +75 | +$10.55K |
| 2026-07-01 | Ajay Mehra | PRESIDENT AND CEO | A | +75 | +$10.55K |
| 2026-05-05 | Deepak Chopra | Director | Sell | −20,000 | −$5.64M |
| 2026-04-24 | W Paul Constantine | PRES., SPACELABS HEALTHCARE | F | −65 | −$19.01K |
| 2026-02-04 | Deepak Chopra | Director | Sell | −20,000 | −$5.02M |
| 2026-01-02 | Michael Tropeano | PRESIDENT, RAPISCAN SYSTEMS | A | +75 | +$10.55K |
| 2026-01-02 | Cary M. Okawa | CHIEF ACCOUNTING OFFICER | A | +52 | +$5.70K |
| 2026-01-02 | Alan I Edrick | EVP & CFO | A | +75 | +$10.55K |
| 2026-01-02 | Deepak Chopra | Director | A | +75 | +$10.55K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Alan I Edrick | EVP & CFO | 306,538 | $62.11M |
| Deepak Chopra | Director | 274,218 | $55.56M |
| Victor S Sze | GENERAL COUNSEL | 115,994 | $23.50M |
| Ajay Mehra | PRESIDENT AND CEO | 115,578 | $23.42M |
| Manoocher M Aliabadi | PRES., OPTOELECTRONICS DIV | 109,356 | $22.16M |
| William Francis Ballhaus JR | Director | 29,475 | $5.97M |
| Meyer/ Luskin | Director | 16,271 | $3.30M |
| Paul Keith Morben | PRES., OPTOELECTRONICS DIV | 11,386 | $2.31M |
| Kelli Bernard | Director | 10,781 | $2.18M |
| Gerald M Chizever | Director | 10,447 | $2.12M |
| Glenn Grindstaff | CHIEF HUMAN RESOURCES OFFICER | 10,193 | $2.07M |
| Shalabh Chandra | PRES., SPACELABS HEALTHCARE | 9,298 | $1.88M |
| James B Hawkins | Director | 5,295 | $1.07M |
| Michael Tropeano | PRESIDENT, RAPISCAN SYSTEMS | 5,003 | $1.01M |
| Cary M. Okawa | CHIEF ACCOUNTING OFFICER | 4,304 | $872.05K |
| W Paul Constantine | PRES., SPACELABS HEALTHCARE | 2,049 | $415.16K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OSIS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.